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Abstract
Background: Mass treatment to trachoma endemic communities is a critical part of the World Health Organization SAFE
strategy. However, non-participation may not be at random, affecting coverage surveys and effectiveness if infection is
differential.
Methodology/Principal Findings: As part of the Partnership for Rapid Elimination of Trachoma (PRET), 32 communities in
Tanzania, and 48 in The Gambia had a detailed census taken followed by mass treatment with azithromycin. The target
coverage in each community was .80% of children ages ,10 years. Community treatment assistants observed treatment
and recorded compliance, thus coverage at the community, household, and individual level could be determined. Within
each community, we determined the actual proportions of households where all, some, or none of the children were
treated. Assuming the coverage in children ,10 years of the community was as observed and non-participation was at
random, we did 500 simulations to derive expected proportions of households where all, some, or none of the children were
treated. Clustering of household treatment was detected comparing greater-than-expected proportions of households
where none or all of children were treated, and the intraclass correlation (ICC) was calculated. Tanzanian and Gambian mass
treatment coverages for children ,10 years of age ranged from 82–100% and 62–99%, respectively. Clustering of
households where all children were treated or no children were treated was greater than expected. Compared to model
simulations, all Tanzanian communities and 44 of 48 (91.7%) Gambian communities had significantly higher proportions of
households where all children were treated. Furthermore, 30 of 32 (93.8%) Tanzanian communities and 34 of 48 (70.8%)
Gambian communities had a significantly elevated proportion of households compared to the expected proportion where
no children were treated. The ICC for Tanzania was 0.77 (95% CI 0.74–0.81) and for The Gambia was 0.55 (95% CI 0.51–0.59).
Conclusions/Significance: In programs aiming for high coverage, complete compliance or non-compliance with mass
treatment clusters within households. Non-compliance cannot be assumed to be at random.
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Introduction
Trachoma is the leading infectious cause of blindness [1]. As the
most common ocular neglected tropical disease, active trachoma is
estimated to affect 40.6 million people worldwide, and another 8.2
million experience visual impairment or blindness [2]. Trachoma
is largely confined to regions of extreme poverty [3].The World
Health Organization (WHO) African region contains more than
two thirds of all active trachoma cases and approximately 47% of
all trichiasis cases [2].
The WHO recommends azithromycin mass drug administra-
tion as a key part of the Surgery, Antibiotics, Face-washing,
Environmental change (SAFE) strategy for eliminating trachoma.
The WHO advocates a treatment coverage goal of at least 80% to
be effective [4]. Although evidence is needed to determine the
impact of coverage at different thresholds, national trachoma
control programs need to be able to measure non-participation in
order to meet distribution targets. Because active trachoma and
infection largely reside in preschool age children within commu-
nities, antibiotic treatment should particularly target this group for
maximal effectiveness [5].
Treatment coverage surveys often carry an implicit assumption
that missing treatment occurs at random. There are no data to
support this conjecture, and this is reason for concern. There are
ample data that trachoma clusters in families and in neighbor-
hoods [6–10], and that transmission within households and across
households does occur [10,11]. If treatment also tends to cluster,
and is differential by infection status, then even the effect of high
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clustering will affect the precision of coverage estimates, and
how one designs coverage surveys.
We examined the clustering of treatment at the household level
using data at baseline from 32 communities in central Tanzania
and 48 communities in The Gambia who are enrolled in the three-
year Partnership for Rapid Elimination of Trachoma (PRET)
project.
Methods
Ethics statement
The study was approved by the Johns Hopkins Medical
Institutional Review Board, the Tanzanian National Institute for
Medical Research, the London School of Hygiene and Tropical
Medicine Ethical Review Board, and The Gambia Government/
Medical Research Council Joint Ethics Committee.
All individual participants for this study provided consent. All
adults provided informed written consent in both The Gambia
and Tanzania.
Populations
The study was conducted in 32, geographically distinct,
communities within the Kongwa district of Tanzania. Communi-
ties were eligible if they were located in the Kongwa district, the
community leadership gave consent, and the estimated community
prevalence of trachoma was greater than or equal to 20% and less
than 50% in preschool age children. We excluded communities
where the estimated population was greater than 5,000 persons. In
Tanzania, a household was defined as persons who used a unique
doorway to sleeping quarters.
In The Gambia, Census Enumeration Areas (EAs) were used as
communities because villages (collection of households with a
distinct name) varied so much in size. The estimated prevalence of
trachoma for most EAs was less than 20% and no EA is larger
than 5,000 persons. The EAs are hereafter referred to as
communities.
Forty-eight Gambian communities participated, located within
four districts: Lower Baddibu, Central Baddibu, Foni Bintang
Karanai, and Foni Kansala. Communities were eligible if they
were located in the target district, community leadership gave
consent to participate in the trial, and they had a prevalence of
active trachoma greater than 5% in preschool age children, based
on the best available data (no community had more than 50%
trachoma). In The Gambia, a household is defined as persons who
all eat together.
These communities varied in size between countries. In
Tanzania, communities averaged around 1500 population. In
The Gambia, communities’ average population size was 700
persons.
Data collection
Details on the PRET project methods, enrollment, and study
procedures are described elsewhere [12] and summarized below.
In Tanzania, prior to mass treatment, trained research staff
conducted a census of every household in the 32 communities.
Baseline census information, the names, age, and gender of all
persons residing in the household, was obtained from the head of
household. Education completed by the head of household,
distance to water, and presence of latrine were also collected for
each household. These data were used to generate treatment
books for mass distribution. In four randomly selected communi-
ties, all children less than ten years were screened at baseline for
active trachoma (trachomatous follicular (TF) and/or trachoma-
tous inflammation-intense (TI)) and ocular infection with Chlamydia
trachomatis, using a commercially available test, Amplicor, which
tests for the chlamydial plasmid (Roche Diagnostics, Indianapolis,
IN). Data from this group were used to determine if non-
compliance with mass treatment was associated with infection
status at the baseline census.
In The Gambia, a census was completed in each of the 48
communities by trained research staff interviewing the head of the
household. The data were used to generate treatment books to
monitor mass treatment.
Treatment
Mass treatment was a single dose of azithromycin, 20 mg/kg up
to one gram. Azithromycin was offered to all members of the
community aged over six months. For children younger than six
months, tetracycline eye ointment was offered, and in The
Gambia, pregnant women were also offered tetracycline eye
ointment as an alternative. The regimen consisted of six weeks of
tetracycline ointment, twice a day. Guardians of children less than
six months were provided with tetracycline, and were responsible
for complying with the regimen. In both countries, the minimum
target for coverage of mass treatment was 80% of children aged
less than ten years.
In Tanzania, a team of Community Treatment Assistants
(CTAs) was trained in each community and assigned specific
neighborhoods. They were given treatment books based on the
census lists. The CTAs were responsible for providing treatment to
all community residents, on pre-announced days. Azithromycin
was offered at a central location in the neighborhood and, if
necessary, at the household, was directly observed and noted in the
treatment books. The CTAs were each provided a small incentive
of 1000 TsH ($0.90) at the conclusion of mass treatment, if
treatment verification showed that recorded treatment agreed with
findings from the household treatment verification. Two to six
CTAs were responsible for each community, and treatment days
varied from two to five. Procedures identical to the National
Program were carried out in Kongwa except that more
supervision was provided and some communities were allowed
additional days.
In The Gambia, a meeting was held with the community
leaders to plan mass treatment for the community. There were
Author Summary
Trachoma, an infectious disease, continues to cause
blindness. A great deal of the trachoma burden is
concentrated in developing countries. The World Health
Organization recommends mass treatment for entire
communities in trachoma-endemic regions. In 32 Tanza-
nian and 48 Gambian communities with trachoma, mass
treatment was directly observed following a census.
Community coverage was mostly greater than 80%.
Larger-than-expected proportions of households where
all children were treated and where none of the children
were treated were found in each country. Household
clustering of treatment was higher in Tanzania compared
to The Gambia. However, children who were not treated
were not more likely to be infected compared to children
who were treated. We found that treatment and non-
treatment within communities does not occur at random
but rather clusters within households. These findings
impact the design of future coverage surveys and suggest
that further research evaluate factors that are associated
with familial non-compliance.
Participation Clusters in Households
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community ophthalmic nurses (CONs) in the community, and a
variable number of ‘friends of the eye’ (nyateros) who were enlisted
to help with distribution. Residents came to a central location
within each community and treatment was directly observed. If
any family member was missing, the family was asked to make sure
the member came before the end of the day for treatment. The
CON was notified in advance of persons who missed mass
treatment, and asked to personally go and inform them of the
subsequent treatment day in their community, and to advise
treatment. One or two treatment days were offered. The drug
distribution itself was provided by the NECP team, who received
per diems of 200 dalasi/day ($7.88). This program was the NECP
treatment for The Gambia.
Statistical analyses
Coverage data was derived from treatment registers completed
by the CTAs. For each community, we calculated the total
coverage as the proportion of the censused population who had
received either a tube of tetracycline or an observed dose of
azithromycin. We calculated coverage of children as the
proportion of children aged less than ten years who had received
a dose of azithromycin or topical tetracycline; the denominator
was all children aged less than ten years resident in the community
during census. For each community, we then took households with
children aged less than ten years and calculated the proportion of
households where all children were treated, where no children
were treated, and where some of the children were treated. This
constitutes the observed proportions for each community.
Next, data were stratified according to community and 500
model simulations of household treatment distributions were run.
These simulations assumed that children were treated and not
treated at random, and for each community, the coverage of
children less than ten years for the simulated data was set equal to
the observed coverage. For each community, the observed
proportions of households where all/none/some of the children
were treated were compared with the simulated data. The
intraclass correlation coefficient (ICC) of treatment status for
children of the same household is reported, as a measure of
clustering.
Because of the large variability of household size in The
Gambia, we compared the ICC of households with fewer than
four children to the ICC of households with four or more children.
To address the question if non-treatment was differential by
infection status prior to treatment in Tanzania, logistic regression
models were employed using treatment as the dependent variable
and infection status prior to treatment as the predictor. We
corrected standard errors to account for the clustering at
household level using the generalized estimating equation
approach.
Results
Approximately 46,634 individuals, including 17,332 children
under ten years, resided in the 32 Tanzanian communities at
baseline. The mean community population in Tanzania was
approximately 1,457 people. Community size ranged from 703–
2496. The mean number of persons per household was similar
across Tanzanian communities, and the average number of
children aged under ten per household was 1.7 (Table 1).
In The Gambia, 33,695 individuals, with 11,321 children below
ten years, lived in the 48 Gambian communities (Table 1). The
Gambia had an average community population of 702 people,
with the size ranging from 327–1621. On average, there were
approximately 11 individuals living in a Gambian household, and
an average of four children aged less than ten years.
Coverage for both settings was high, reflecting the target of
greater than 80% (Table 2). In Tanzania, the average coverage
was 94% for children under age ten, ranging from 81%–100% in
children 0–9 years and 65%–100% for all ages. The Gambian
average coverage for children below age ten was lower, 89%,
ranging from 62 to 99%. The range for total coverage of the
population was 62 to 98%, with a mean coverage of 86%, similar
to Tanzania.
In both Tanzania and The Gambia, most households had all
children treated (Table 3). The percentage of households where all
children were treated, and the percentage of households where no
child was treated, were both greater than would be predicted if
non-treatment occurred at random, although the evidence for
clustering was less strong in The Gambia (Figure 1).
In Tanzania, the ICC for treatment status of children within
households was 0.77 (95% CI 0.74–0.81). The mean percentage of
households where no children under ten were treated was 4.6%
(95% CI 3.2%–6.1%) compared to the estimate based on
simulation with the presumption of non-treatment at random of
2.2% (95% CI 1.4%–2.9%).The mean percentage of households
where all children were treated was 90.3% (95% CI 87.8%–
92.8%), compared to the estimate based on simulation of 87.7%
(95% CI 84.4%–90.1%). Thirty of 32 communities (94%) had
greater than the predicted proportion of households with none of
the children treated, if non-treatment was at random.
In The Gambia, the ICC was 0.55 (95%CI 0.51–0.59). On
average, the percentage of households with no children treated
was 4.8% (95% CI 3.0%–6.7%) compared to the estimate from
simulations of 2.1% (95% CI1.5%–2.7%). The mean percentage
of households with all children treated was 74.2% (95% CI
70.1%–78.3%) versus the estimate from simulations of 67.0%
Table 1. Baseline characteristics of communities by country.
Tanzania The Gambia
Number of communities 32 48
Total population 46634 33695
Child population (under 10 years) 17332 11321
Average number of households
across communities (SD)
312.8 (87.0) 65.0 (20.9)
Average household size across
communities (SD)
4.7 (0.32) 10.9 (2.0)
Average population across
communities (SD)
1457.3 (429.0) 702.0 (243.1)
Average child population
across communities (SD)
541.6 (180.1) 235.9 (86.0)
doi:10.1371/journal.pntd.0000838.t001
Table 2. Average mass treatment coverage in communities
by country.
Tanzania The Gambia
Average community coverage
of children (SD)
94.0 (5.1) 88.7 (7.6)
Average community coverage
of total population (SD)
88.7 (9.6) 86.2 (7.9)
doi:10.1371/journal.pntd.0000838.t002
Participation Clusters in Households
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(70.8%) had significantly higher numbers of households with no
children treated, compared to prediction if non–treatment was at
random.
Because the range of household size was much greater in The
Gambia, we compared the ICC for households with less than four
children aged under ten years, to the ICC for households with four
or more children in the Gambian data. For smaller household size,
the ICC was 0.60 (95% CI 0.54–0.65), compared to Tanzania
which was 0.77. The ICC was significantly lower for Gambian
households with four or more children aged less than ten years,
0.50 (95% CI 0.45–0.56).
In the four Tanzanian communities where infection status was
available for all children under ten years of age, households where
none of the children were treated were no more likely to have
children with infection than households where at least one child
was treated (odds ratio 0.82 (95% CI 0.54–1.27). The PCR swab
positive infection rate prior to treatment in children who were not
treated was not statistically significantly different than that for
children who were treated, 16.8% versus 23.9%, p=0.09.
Discussion
Our study in two different settings shows that in communities
that carry out azithromycin mass treatment with high coverage,
non-treatment (as well as all-treatment) of children clusters in
households. There was strong evidence that treatment (and non-
treatment) did not occur at random. Compared to assumptions of
random non-treatment, we demonstrated significant levels of
treatment and non-treatment clustering within households in
Tanzania and The Gambia. A number of community programs
for other diseases have also observed household clustering of
treatment [13–15], and we have now found a similar trend for
trachoma mass treatment.
Tanzanian households were more homogenous with respect to
treatment compared to The Gambia. In part, this appears to be
driven by the larger household size in The Gambia, where we
observed higher ICC for households with less than four children
compared to households with four or more children. With
increasing numbers of children in a household, the bar is clearly
higher for reaching ‘‘all children treated.’’ However, the ICC for
Tanzania with four or fewer children was still greater than for The
Gambia. This may also reflect differences in the approach to
obtaining high coverage, and the higher coverage achieved in
Tanzania. For children aged 0–9 years, Tanzanian communities
had a 94% coverage compared to The Gambia’s coverage of 89%.
As coverage levels among children drop, it appears that the
likelihood of more partially covered households increases.
Our data demonstrate that non-participation clusters, and that
national programs should develop strategies to identify and treat
households that do not participate, with examples of possible
reasons for non-participation supported by the literature [16–18].
Our results support the argument that participation in public
health programs is dependent on a number of social factors, which
differ among households.
Our findings provide evidence that non-participation in mass
drug administration is a non-random event; therefore, coverage
surveys using cluster-sampling design should include a design
effect to ensure that they have an appropriate sample size. If
surveys estimate the number of persons treated, then an
assumption that non-treatment is at random will result in sample
sizes that are underpowered, and have the potential for erroneous
estimates whose directionality is unpredictable. The design effect
for Tanzania, for example, is 1.6 for an average household size of
1.8 children; because of the larger cluster size in The Gambia, the
design effect is 2.7. A greater design effect means more household
clusters must be included to achieve a minimum appropriate
sample size.
In Tanzania, we also showed that prior to treatment, households
with no treated children were no more likely to have at least one
child with ocular C. trachomatis infection as households withsome/all
children treated. Consequently, households opting out of the
treatment are not more likely to be infected, and thus do not
represent a disproportionate threat to re-emergence within the
community. If infection had been associated with households where
none of the children was treated, even programs with high target
coverage would have a more challenging job maintaining any
reduction in trachoma prevalence. We also showed that infection
rates prior to treatment were no different in children who were
untreated compared to children who were treated, so while infected
children still represent a threat of re-emergence, they are not
differentially located in the untreated group. There was insufficient
infection at baseline in The Gambia to address this question.
Although our study did not measure risk factors associated with
participation, other community-based studies have shown that
Figure 1. Comparison of expected vs. observed households
with none/all children treated. The percentages of expected
households were derived from simulations. Within each panel, each
dot represents a community.
doi:10.1371/journal.pntd.0000838.g001
Table 3. Household treatment status by country.
Tanzania The Gambia
% of households where all
children were treated
89.8 75.2
% of households where some
children treated
5.4 20.2
% of households where none of
the children were treated
4.8 4.6
doi:10.1371/journal.pntd.0000838.t003
Participation Clusters in Households
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of family support for treatment [20], and increasing distance from
the distribution site [21] were associated with non-participation.
However, there is a need to investigate further the household
factors related to clustering of non-treatment of children. Such
research would help trachoma control programs by deepening
their understanding of factors that might be altered to improve
familial mass treatment participation.
We observed that where coverage in children was higher, the
households tended to be more homogenous with respect to
treatment. It may be easier for CTAs to encourage a guardian who
has had some of their own children participate in mass treatment
to treat the remaining family members, than to convince a
guardian who has not brought any children for treatment to
participate. In addition, with increasing number of days of mass
treatment, it likely becomes easier to return to households a
sufficient number of times to reach persons who may have been
away. Consequently, as efforts persist to improve coverage, it may
be that most households will have all members treated, or
households will cluster with all non-treated members, and the
community will consist of relatively fewer numbers of partially
treated households.
There are some limitations to our analyses. In both countries,
target coverage was very high, above 80%, thus limiting the
generalizability of findings to communities where coverage rates
are much lower; however, this is the coverage target that is
recommended by WHO for trachoma control programs. We also
constrained, for the simulations, the overall coverage in the
community to match the observed coverage. Other approaches
could have been used, such as taking the overall coverage for all
communities combined. However, we wanted to assess household
clustering, so using the overall community level value as the target
for each community let us simulate treatment of children at
random within the community. Finally, CTAs may have been
tempted to report better than average coverage. However,
treatment verification procedures reported excellent correspon-
dence between CTA records and verification (fewer than 1%
discrepancies).
In summary, we measured treatment clustering within house-
holds of countries with moderate and low trachoma infection,
Tanzania and The Gambia, in the context of achieving high
coverage rates. Participation in azithromycin mass treatment was
not at random. Most communities had higher numbers of
household with either all-treated or none-treated children. As
treatment clustering is at the household level, an evaluation of
household risk factors related to clustering may assist in
understanding this phenomenon and contribute to the develop-
ment of trachoma control programs with higher coverage.
Regardless, national trachoma control programs need a plan to
capture children who may be missed in mass treatment campaigns,
and ensure continued participation through multiple rounds.
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